{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_citation in Reference Text / Citation (approximate match)
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02957266: Phase 3 Interventional Unknown status Cervical Cancer
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04210245: Phase 2 Interventional Completed Compensated Cirrhosis
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00354926: Phase 1 Interventional Completed Non-Hodgkin's Lymphoma
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04176133: Phase 2 Interventional Completed Healthy
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tiprelestat [INN]
Source URL:
Class:
PROTEIN
Tiprelestat (Elafin) is a potent Human neutrophil elastase inhibitor. Elafin is identical to the human protein elafin with high specificity for tissue destroying and inflammation promoting proteases. The development program of Elafin is focused on the late stage development of Elafin in major surgery and early stage development in pulmonary arterial hypertension (PAH). Elafin has received orphan drug designations in the USA and the EU for esophageal cancer surgery (ECS) and PAH. Tiprelestat is in phase II clinical trials for the treatment of myocardial reperfusion injury, postoperative inflammation and in phase I clinical trial for the treatment of pulmonary arterial hypertension.
Status:
Investigational
Source:
Leuk Lymphoma. Apr 2011;52(4):587-96.: Phase 3 Human clinical trial Completed Lymphoma, B-Cell/therapy
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02462928: Phase 3 Interventional Completed Macular Degeneration
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00504608: Phase 1/Phase 2 Interventional Completed Infertility Implantation Failure
(2003)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:110898
Source URL:
Class:
PROTEIN
